The Latest Cardiac and Vascular News
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September…
Non-dilutive $7.45M Phase III SBIR Temporary Vascular Occlusion Clamp (TVOC) contract to commercialize innovative technology targeting hemorrhage control for the U.S. Air Force. CAMBRIDGE, Mass., Oct. 2, 2024 /PRNewswire/ — Amsel Medical Corporation today announces that it has been…
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System. “Securing FDA clearance for the Pounce XL Thrombectomy System is a major step […]
WASHINGTON, Oct. 1, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) announced today during their Annual Scientific Meeting the launch of a new journal, JCF-Intersections (JCF-I), in partnership with Elsevier. This new journal will join the JCF Family of Journals, led by…
Study will assess the Company’s Next-Generation device under Intracardiac Echocardiography (ICE) imaging for Left Atrial Appendage Occlusion (LAAO) procedures. NASHUA, N.H., Oct. 1, 2024 /PRNewswire/ — Conformal Medical, Inc. today announced the initiation of the GLACE Study. This…
NEW YORK, Oct. 1, 2024 /PRNewswire/ — Remedy Pharmaceuticals today announced additional promising data from the Phase 3 CHARM clinical trial of CIRARA (IV glyburide) in patients with Large Hemispheric Infarction (LHI), the most serious form of ischemic stroke, characterized by…
NEW YORK–(BUSINESS WIRE)–Synchron, a brain-computer interface company, today announced positive results from the COMMAND study evaluating the safety and efficacy of the Synchron brain computer interface (BCI) device in six participants over a 12-month period. “The COMMAND study results represent a major medical milestone, confirming the safety of the Stentrode […]
REHOVOT, Israel–(BUSINESS WIRE)–Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market clearance for ShortCut™ – the world’s first dedicated leaflet modification device, enabling valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures […]
– Results from the placebo-controlled study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) were presented in a Late Breaking Clinical Trial Plenary Session at the HFSA Annual Scientific Meeting 2024 – – Data showed patients treated with HU6…
BENTONVILLE, Ark., Sept. 30, 2024 /PRNewswire/ — HeartX, powered by HealthTech Arkansas and MedAxiom — along with numerous leading cardiology practices in Arkansas and around the country — has selected four startup healthcare companies to participate in its 2024 accelerator program….
